Favorable interaction of β-l(−) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

[1]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[2]  J. Wakefield,et al.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs , 1994, Antimicrobial Agents and Chemotherapy.

[3]  G. Dutschman,et al.  Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro , 1994 .

[4]  E. White,et al.  Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs. , 1993, Antiviral research.

[5]  W. Parker,et al.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism , 1993, Antimicrobial Agents and Chemotherapy.

[6]  R F Schinazi,et al.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.

[7]  B. Anderson,et al.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Richman,et al.  Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection , 1992, Annals of Internal Medicine.

[9]  R F Schinazi,et al.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine , 1992, Antimicrobial Agents and Chemotherapy.

[10]  M. Hirsch,et al.  Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[11]  S. Cox.  Metabolism of 3′-Azido-3′-Deoxythymidine and 3′-Fluoro-3′-Deoxythymidine in Combination in Human Immunodeficiency Virus Infected Lymphoblastoid Cells , 1992 .

[12]  J. Mellors,et al.  In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. , 1992, Molecular pharmacology.

[13]  J. Cameron,et al.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[14]  A. Huang,et al.  Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells , 1991, Antimicrobial Agents and Chemotherapy.

[15]  B. Larder,et al.  Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy , 1990, The Lancet.

[16]  D. Richman,et al.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay , 1990, Antimicrobial Agents and Chemotherapy.